Under one in 10 patients eligible to benefit from obesity jabs like Wegovy have access to them, warns the WHO as it publishes its initial recommendations on the medications.
Considering more than one billion people worldwide currently living with obesity, it is urging increased and just access to this class of drugs.
Per forecasts, over two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance acknowledges that obesity is a chronic disease that can be managed with holistic and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key barriers to broad access to the jabs that can aid individuals in losing considerable body mass, explains the agency.
Skinny Jab Supply Crisis
Even in the current most optimistic outlook, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of the global need, according to the health organization.
The recommendation urges nations and manufacturers to widen availability, through approaches including patent sharing.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
The Way Obesity Injections Function
The injections replicate a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so users consume fewer calories.
People usually begin shedding pounds after several weeks of beginning the regular doses.
Studies suggests users may regain a significant portion after a year of halting the drug, because their normal appetite come back.
To be overweight or obese elevates your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight impacts people in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the health agency.